# USA: navigate federal research rules and state programs together

Regulatory planning · Verify the current product and jurisdiction. The US legal map must identify the particular cannabis product and activity. An April 28, 2026 federal final rule addresses Schedule III treatment for defined FDA-approved and qualifying state-medical products while retaining controls. The DEA also maintains a broader rescheduling docket. Neither a scheduling change nor a state license should be presented as unrestricted nationwide adult-use legalization. Recheck effective rules and any litigation before committing funds.

Canonical page: https://givegigs.com/wiki/necro-chapter-cannabis-usa-law
Last updated: 2026-11-09T18:58:12.584Z
Parent topic: [necromancer-cannabis](https://givegigs.com/wiki/necromancer-cannabis)

## Contents
- [Overview](#wiki-section-overview-1)
- [Chapter notes](#wiki-section-chapter-notes-2)
- [Dossier section](#wiki-section-dossier-link-3)

<a id="wiki-section-overview-1"></a>
## Overview

Regulatory planning · Verify the current product and jurisdiction. This page expands the “USA: navigate federal research rules and state programs together” chapter in the cannabis collection.

<a id="wiki-section-chapter-notes-2"></a>
## Chapter notes

The US legal map must identify the particular cannabis product and activity. An April 28, 2026 federal final rule addresses Schedule III treatment for defined FDA-approved and qualifying state-medical products while retaining controls. The DEA also maintains a broader rescheduling docket. Neither a scheduling change nor a state license should be presented as unrestricted nationwide adult-use legalization. Recheck effective rules and any litigation before committing funds.

For a US investigational drug study, obtain specialist advice on FDA investigational-new-drug requirements, applicable DEA registrations and protocols, institutional review board approval, state permissions, and lawful sourcing. Document the route for the proposed formulation and intended study rather than assuming a dispensary purchase qualifies as research supply. The FDA's cannabis research framework is a starting reference, with current agency confirmation needed for the project.

A Philippine–USA collaboration should begin with shared methods, training, and appropriately governed data. Any transfer of cannabis, biological samples, or identifiable records requires its own legal review and permissions. US state retail access does not authorize international shipping or a Philippine trial. Assign responsibility for federal, state, local, and Philippine compliance before describing the project as a cross-border center.

<a id="wiki-section-dossier-link-3"></a>
## Dossier section

[Open this exact section in the Necromancer dossier](/necromancer#cannabis-usa-law). The original chapter status is “Regulatory planning · Verify the current product and jurisdiction.”

## Sources

- [April 28, 2026 marijuana scheduling final rule](https://www.govinfo.gov/content/pkg/FR-2026-04-28/html/2026-08176.htm)
- [Marijuana Rescheduling Regulatory Actions](https://www.dea.gov/marijuana-rescheduling-regulatory-actions)
- [FDA and Cannabis: Research and Drug Approval Process](https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process)

---
This article is collaboratively maintained. Check the canonical page and cited sources for the latest context.